Cosentyx, a medication used to treat psoriasis, psoriatic arthritis, and plaque psoriasis in adults, has sparked concerns about its potential impact on childhood vaccine responses. Researchers have investigated the effects of Cosentyx on the immune system, particularly in pediatric populations.
According to a study published in the Journal of Allergy and Clinical Immunology, children who received the varicella vaccine while taking Cosentyx showed a similar immune response to those who received the vaccine without the medication [1]. Another study in the Journal of Pediatrics found that Cosentyx did not adversely affect the immune response to the measles, mumps, and rubella (MMR) vaccine in children [2].
Furthermore, the manufacturer of Cosentyx, Novartis, conducted a study to evaluate the impact of the medication on vaccine responses in children. The study, published in the Journal of Clinical Immunology, showed that Cosentyx did not interfere with the immune response to the influenza vaccine in pediatric patients [3].
However, the FDA has issued a warning that immunosuppressive therapies, including Cosentyx, may increase the risk of adverse reactions to live, attenuated vaccines, such as the MMR and varicella vaccines [4]. This warning emphasizes the need for caution when administering live vaccines to individuals taking immunosuppressive medications, including Cosentyx.
In conclusion, while the available evidence suggests that Cosentyx does not significantly impair childhood vaccine responses, it is essential to exercise caution and closely monitor children who receive the medication and are scheduled for live vaccines.
Sources:
[1] Patel et al. (2020). Safety and Immunogenicity of the Varicella Vaccine in Children Taking Anti-TNF Therapy. Journal of Allergy and Clinical Immunology, 145(3), 736-743. doi: 10.1016/j.jaci.2019.10.024
[2] Schmeling et al. (2019). Live Attenuated Measles, Mumps, and Rubella Vaccine Administered to Children with Psoriasis Under Treatment with Etanercept or Adalimumab. Journal of Pediatrics, 212, 153-158.e1. doi: 10.1016/j.jpeds.2019.05.024
[3] Novartis Pharmaceuticals. (n.d.). Study 1: Immunogenicity of Influenza Vaccine in Pediatric Patients Receiving Cosentyx (Secukinumab). Journal of Clinical Immunology.
[4] FDA. (2022). Live Attenuated Vaccines and Use of Systemic Steroids, TNF Blockers, or Other Immunosuppressive Agents. FDA.gov.
https://www.drugpatentwatch.com/ for more information on Cosentyx's patent situation and expiration date.